The expression levels of EZH2 and DNMT3B were decreased in stage IV-V CKD patients; however, expression increased under PD treatment, and PD therapy in 5/6Nx rats induced EZH2 and DNMT3B expression significantly, which indicated that epigenetic mechanisms involving EZH2 and DNMT3B might play crucial roles in peritoneum angiogenesis and remodelling in PD. This evidence concerns the gene EZH2 and chronic kidney disease.